Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cetuximab sarotalocan sodium
- Development stage
- Phase 3
- Lead developer
- Rakuten Medical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cetuximab sarotalocan sodium is an **antibody-drug conjugate (ADC)** combining the anti-EGFR chimeric monoclonal antibody cetuximab (IgG1 subclass) with the photosensitizer sarotalocan sodium (a phthalocyanine derivative, IR700). The conjugate binds to **epidermal growth factor receptor (EGFR)** on the surface of tumor cells. Upon irradiation with a 690 nm laser (BioBlade laser system), the photosensitizer is activated, triggering rapid and selective tumor cell death by photoimmunotherapy. This mechanism leverages both antibody targeting and light-induced cytotoxicity. Developed with the Illuminox platform, the therapy is indicated and approved in Japan for **unresectable locally advanced or recurrent head and neck cancer** and is under investigation for additional solid tumor types including cutaneous squamous cell carcinoma and esophageal cancer[1][2][5][7][8].
- Brand names
- Akalux
- Other names
- cetuximab sarotalocancetuximab-irdye 700dx conjugatecetuximab-irdye700dx conjugatecetuximab-irdye-700dx conjugateセツキシマブサロタロカンナトリウム
02
Targets
Beyond the preview
Go deeper on cetuximab sarotalocan sodium.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cetuximab sarotalocan sodium.